中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

16 records (took 0.017 seconds)

    PD-1 peptide inhibitors
    11.
    发明专利
    PD-1 peptide inhibitors 未知

    公开(公告)号：AU2017325866A1

    公开(公告)日：2019-04-18

    申请号：AU2017325866

    申请日：2017-09-15

    Applicant: LEIDOS INC

    Inventor： GUTIERREZ GABRIEL M ,  KOTRAIAH VINAYAKA ,  PANNUCCI JAMES ,  AYALA RAMSES

    IPC: C07K7/08 ,  A61K38/10 ,  A61P31/00 ,  A61P35/00

    Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor "programmed death 1" (PD-1). These peptides block the interaction of PD-1 with its ligand PDL1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.

    PD-1 AND CTLA-4 DUAL INHIBITOR PEPTIDES
    12.
    发明专利
    PD-1 AND CTLA-4 DUAL INHIBITOR PEPTIDES 未知

    公开(公告)号：CA3064023A1

    公开(公告)日：2018-11-29

    申请号：CA3064023

    申请日：2018-05-25

    Applicant: LEIDOS INC

    Inventor： GUTIERREZ GABRIEL M ,  KOTRAIAH VINAYAKA ,  PHARES TIMOTHY ,  PANNUCCI JAMES

    IPC: C07K14/705 ,  A61K38/17

    Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor "programmed death 1" (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 as well as the interaction of CTLA4 with CD86 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.

    VIRAL CONSTRUCTS FOR USE IN ENHANCING T-CELL PRIMING DURING VACCINATION
    13.
    发明专利
    VIRAL CONSTRUCTS FOR USE IN ENHANCING T-CELL PRIMING DURING VACCINATION 未知

    公开(公告)号：AU2022215566A9

    公开(公告)日：2025-01-30

    申请号：AU2022215566

    申请日：2022-02-02

    Applicant: GEOVAX INC ,  LEIDOS INC

    Inventor： HAUSER MARY JO ,  DOMI ARBAN ,  GUTIERREZ GABRIEL ,  PANNUCCI JAMES ,  KOTRAIAH VINAYAKA ,  PHARES TIMOTHY ,  BUONTEMPO PETER ,  BROWNE CECILLE

    IPC: A61K35/768 ,  C12N15/86 ,  C12N15/87 ,  C12N15/90

    Abstract: The invention provides virus-based expression vectors comprising immune-checkpoint inhibitor inserts for use as effective adjuvants in enhancing T-cell priming to an antigen in a host during a vaccination regimen. In particular, the compositions described herein are novel recombinant modified vaccinia Ankara (MVA) viral constructs encoding one or more peptides which, upon administration, are expressed in a multimer conformation and subsequently cleaved and secreted from the cell. Such peptides are capable of downregulating an immune checkpoint pathway, for example, by inhibiting the activation of programmed-cell death protein 1 (PD-1), programed cell death ligand 1 (PD-L1), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), or another immune checkpoint regulator, or a combination thereof. When used in concert with the administration of an antigen during a vaccination strategy, the immune checkpoint expressing MV A viral construct provides significantly improved antigen-specific CD8+ T cell expansion, increased antigenic responses, and improved vaccination efficacy.

    LAG 3 binding peptides
    14.
    发明专利
    LAG 3 binding peptides 未知

    公开(公告)号：AU2020279371A1

    公开(公告)日：2021-12-23

    申请号：AU2020279371

    申请日：2020-05-21

    Applicant: LEIDOS INC

    Inventor： GUTIERREZ GABRIEL M ,  KOTRAIAH VINAYAKA ,  PHARES TIMOTHY W ,  PANNUCCI JAMES ,  MANSOUR MARC

    IPC: A61P35/00 ,  A61P25/28 ,  C07K7/00

    Abstract: This disclosure provides peptides which bind to LAG3 and can be used to block the interaction of LAG 3 with other molecules such as MHC-II, FGL1, and α-synuclein. These peptides can be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, or inhibiting the progression of a synucleinopathy, inhibiting the progression of sepsis, inhibiting the progression of an infectious disease, and enhancing a response to a vaccine.

Patent Agency Ranking